Lonza Group vs Northwest
the patent complaint
patentdocs.net
Lonza Group AG v. Northwest Biotherapeutics, Inc.
8:07-cv-03177; filed November 27, 2007 in the District Court of Maryland
Infringement of U.S. Patent Nos. 5,122,464 ("Method for Dominant Selection in Eucaryotic Cells," issued June 16, 2992), 5,591,639 ("Recombinant DNA Expression Vectors," issued January 7, 1997), 5,658,759 (same title, issued August 19, 1997), 5,770,359 ("Recombinant DNA Sequences, Vectors Containing Them and Method for the Use Thereof," issued June 23, 1998), 5,827,739 (same title, issued October 27, 1998), 5,879,936 ("Recombinant DNA Methods, Vectors and Host Cells," issued March 9, 1999), 5,891,693 (same title, issued April 6, 1999), and 5,981,216 ("Transformed Myeloma Cell-Line and a Process for the Expression of a Gene Coding for a Eukaryotic Polypeptide Employing Same," issued November 9, 1999) based on Northwest's manufacture, use, and sale of its DCVax® products, including DCVax®-Prostate, used to treat prostate cancer. View the complaint here.
patentdocs.net |
